Aurobindo Pharma in licensing pact with AstraZeneca

摘要

Aurobindo Pharma has entered into licensing and supply agreements with AstraZeneca to supply solid dosage and sterile products for emerging markets. These products fall under a broad range of important therapeutic segments such as anti-in-fectives, cardiovascular system and central nervous system. Financial terms were not disclosed. The agreements will support AstraZeneca's investment in branded generics sold in emerging markets, said a company press note.